FHR-3, Human, ELISA kit

Human Complement Factor H-related protein 3 (FHR-3) is a crucial glycoprotein within the complement regulatory protein family. Synthesized mainly by the liver, FHR-3 is also produced by immune cells like monocytes and macrophages. This protein manifests in the plasma as multiple glycosylated forms, ranging between 35 to 56 kDa. Sharing structural similarities with Complement Factor H (CFH), FHR-3 is a significant player in the complement system’s regulatory network, particularly within the alternative pathway.
The exact role of FHR-3 in complement regulation remains to be fully deciphered. Preliminary studies suggest it has weak cofactor activity, potentially enhancing FH cofactor activity, and shows a limited inhibitory effect in hemolytic assays using FH-depleted serum. However, further research is needed to validate these findings.
In terms of clinical implications, aberrations in human FHR-3 expression or function are associated with diseases such as atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and systemic lupus erythematosus (SLE). In these conditions, improper complement activation and tissue deposition play a role in disease pathology.
The role of FHR-3 in the Alternative Pathway underscores its importance in disease mechanisms. Its significant impact makes it a promising therapeutic target for diseases affected by complement dysregulation. Understanding FHR-3’s involvement in these processes is vital for developing effective strategies to control complement-driven diseases. FHR-3 can be measured with our HK3005 assay, designed to precisely quantify this intriguing glycoprotein.